HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Autobio Diagnostics (603658.CH) - The Turning Point Is Quietly Approaching

Industry Report - Insights on China IVD Industry

Industry Report: Insights on China IVD Industry - The POCT Market

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Zhejiang Orient Gene Biotech C / Equity Bottom-Up

Zhejiang Orient Gene Biotech C (688298 CH)

<p><a href="https://www.smartkarma.com/entities/zhejiang-orient-gene-biotech-a" target="_blank" data-smartkarma-citation="entities:30379:1" rel="noopener">Zhejiang Orient Gene Biotech-A (688298 CH) </a>(Orient Biotech) is a company specializing in the R&amp;D, production and sales of IVD products, with main business in the field of POCT (point-of-care testing). According to its financial reports, Orient Biotech achieved high growth in both 2020 and 2021Q1. In 2020, the revenue was RMB3.265 billion, up 788.83% YoY. Net profit attributed to shareholders was RMB1.677 billion, up 1,942.94% YoY. In 2021Q1, the Company achieved revenue of RMB2.236 billion, up 1925.91% YoY. Net profit attributed to shareholders was RMB1.186 billion, up 2601.42% YoY. This insight mainly analyzed the industry characteristics, the business, the valuation and the key risks of Orient Biotech.</p>

Zhejiang Orient Gene Biotech-A (688298 CH) (Orient Biotech) is a company specializing in the R&amp;D, production and sales of IVD products, with main business in the field of POCT (point-of-care testing). According to its financial reports, Orient Biotech achieved high growth in both 2020 and 2021Q1. In 2020, the revenue was RMB3.265 billion, up 788.83% YoY. Net profit attributed to shareholders was RMB1.677 billion, up 1,942.94% YoY. In 2021Q1, the Company achieved revenue of RMB2.236 billion, up 1925.91% YoY. Net profit attributed to shareholders was RMB1.186 billion, up 2601.42% YoY. This insight mainly analyzed the industry characteristics, the business, the valuation and the key risks of Orient Biotech.

Zhejiang Orient Gene Biotech (688298.CH) - Clearly Undervalued with Attractive Upside Potential